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Background: Opioid-induced constipation (OIC) is one of the major symptoms in palliative care with a prevalence
of 30-50%. Methylnaltrexone for the treatment of OIC is significantly more effective than placebo, but only in about
fifty percent of the patients regardless of dose increase. Dose increases cause increased toxicity without additional
efficacy, and are therefore not recommended.
While methylnaltrexone is a μ-receptor antagonist, only a few opioids are solely μ-receptor agonists. Therefore, the
response to methylnaltrexone may be determined by the receptor-profile of a specific opioid. In addition,
methylnaltrexone may also affect the immune system and angiogenesis as was found in pre-clinical studies. Primary
aim of this study is to determine differences in the efficacy of methylnaltrexone prescribed to resolve opioid induced
constipation between three commonly used opioid subtypes: morphine sulphate, oxycodone and fentanyl. Secondary
aim is to explore potential immunomodulatory and antiangiogenic effects of methylnaltrexone.
Methods: In this multi-center, prospective, parallel group trial we will evaluate the efficacy of methylnaltrexone in
resolving OIC occurring as a side effect of the most common opioid subtypes: morphine, oxycodone and fentanyl.
In total 195 patients with OIC despite prophylactic laxatives will receive methylnaltrexone every other day up to
fourteen days. Patients will report its effect in a laxation diary. Group allocation is based on the opioid type the
patient is using. At the start and end of the study period patients complete the Bowel Function Index questionnaire.
A subgroup of the patients will donate blood for analysis of immunomodulatory- and anti-angiogenic effects of
methylnaltrexone.
Discussion: In this study we aim to determine the efficacy of methylnaltrexone per opioid subtype to reduce
constipation. We expect that the outcome of this study will improve the clinical use of methylnaltraxone.
Trial registration: This trial is registered at clinicaltrials.gov: NCT01955213 and in the Dutch trial register: NTR4272.
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Constipation is one of the major symptoms in palliative
care, with a prevalence rate of 30-50% in patients with
cancer [1,2]. It leads to a noticeable decrease in quality
of life [3] by causing physical symptoms such as bloating
and straining, and sometimes necessitates hospitalization
[4]. Constipation can have multiple causes, which can be
divided into anorectal dysfunction, or slow colon transit
[5]. In palliative care for patients with cancer mechanical
obstruction by tumor depositions or ascites might also
be a cause of constipation, but often constipation is
caused by opioid use. The incidence of opioid induced
constipation (OIC) is estimated to vary between 35 and
70% of the patients using opioids [4,6-8]. This large
range is probably caused by variation in type and dosage
of opioids, the amount of (prophylactic) laxatives used
and the way patients are monitored for this side effect in
different studies [4,6-8]. The Rome criteria (currently
version III) are generally used to diagnose constipation
[5]. According to the Rome III criteria for constipation,
a patient must have experienced at least 2 of the follow-
ing symptoms over the preceding 3 months with symp-
tom onset at least 6 months before diagnosis: fewer than
3 bowel movements per week, straining, lumpy or hard
stools, sensation of anorectal obstruction, sensation of
incomplete defecation, and/or manual maneuvering re-
quired to defecate. However, these diagnostic criteria
might not be applicable to patients with OIC, because
they require the presence of complaints for at least six
months, while OIC usually develops within days to
weeks and might need urgent treatment. Therefore, a
practical definition of OIC is a decrease of the fre-
quency of bowel movements after initiation of opioids
to a frequency of less than three bowel movements per
week [9]. To prevent OIC, guidelines recommend prophy-
lactic laxatives [10,11]. Most patients are able to manage
their bowel movements by in- or decreasing the dosage of
the laxatives they use. However, 12-20% of the patients
report symptoms of OIC despite laxative prescription
[12]. For these patients methylnaltrexone, a peripher-
ally acting μ-opioid receptor antagonist, can be a valu-
able therapeutic option.
Opioids exert their action through the opioid-receptors.
These receptors are present in the central nervous system
but also in peripheral tissues. Under normal conditions
opioid receptors are receptive to endogenous opioids,Table 1 Opioid characteristics regarding constipation
Opioid Receptor affinity Lipophilicity
Morphine Sulphate Mainly μ, some κ Low
Oxycodone μ, κ and δ Intermediate
Fentanyl μ (highly selective) High
1Estimated incidence of constipation without laxative use and the range of this inci
uses laxatives.such as enkephalins and endorphins [13]. The three major
types of opioid receptors are the mu (μ), kappa (κ) and
delta (δ) opioid receptor [13]. The affinity for the different
receptors varies between different types of opioids [13].
How each receptor type contributes to OIC is not fully
understood. There is evidence that each receptor type has
an effect on gastro-intestinal motility and fluid secretion
[14]. Previous studies suggest that these effects are mainly
mediated by the peripheral opioid receptors [14-16].
Methylnaltrexone
Methylnaltrexone (Relistor®) is an opioid receptor antag-
onist which blocks opioid binding at the μ-receptor but
also has some affinity for the κ-receptor. It is a quater-
nary derivative of naltrexone with restricted ability to
cross the blood–brain barrier. It therefore functions as a
peripherally acting opioid antagonist, which reduces the
opioid-induced decrease in gastrointestinal motility and
delay in gastrointestinal transit time, and thereby re-
duces OIC. Methylnaltrexone does not affect opioid an-
algesic effects or induce opioid withdrawal symptoms. It
is excreted by the kidneys and in the feces and has a
plasma half life of approximately 8 hours. The most
common side effects of methylnaltrexone are abdominal
pain, nausea, flatulence, and diarrhea, which are likely to
be related to increased peristaltic activity [17]. Methyl-
naltrexone has been approved by the FDA and EMA for
patients who receive palliative care (regardless of med-
ical condition) with OIC despite prophylactic laxative
use.
Methylnaltrexone for the treatment of OIC is signifi-
cantly more effective than placebo [9]. However, in both
the randomized and open-label phases of the pivotal
multi-center trial, methylnaltrexone produced rescue-
free laxation in only about half the patients [9]. Dose in-
creases did not influence these results [18]. There may
be several reasons for this observation. First, constipa-
tion in palliative care patients may have multiple simul-
taneously occurring causes, unrelated to opioid therapy.
Second, assuming that the constipation of the non-
responders is still opioid-induced, one can hypothesize
that the response to methylnaltrexone could be deter-
mined by the receptor-profile of the specific opioid the
patient is using (Table 1) [4,6-8,19]. This is because
methylnaltrexone is primarily a μ-receptor antagonist,
while not all opioids are solely μ-receptor agonists. ADistribution site Incidence of constipation1
Peripheral 60% (range 21-70%)
Central and peripheral 65% (range 25-74%)
Central 35% (range 10-55%)
dence found in different studies in which a proportion of patients already
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and δ-receptor agonist [13] as well as μ-receptor agonist,
whereas morphine and fentanyl are both mainly μ-receptor
agonists. Morphine and fentanyl, on the other hand, differ
in their lipid solubility and their tendency to sequestrate in
the central nervous system [13]. This may possibly contrib-
ute to differences in response to methylnaltrexone, because
methylnaltrexone is unable to pass the blood–brain barrier.
In all previously mentioned studies no comparison
was made between the response rates to methylnaltrex-
one of patients using different types of opioids [9,17].
Therefore, we recently initiated a clinical trial to deter-
mine whether different receptor-profiles of opioids are
related to the efficacy of methylnaltrexone.
Besides constipation, there are other side effects of
opioids that might be of clinical importance. Acute and
chronic use of opioids is known to have inhibitory ef-
fects on humoral and cellular immune responses and may
also have a stimulating effect on angiogenesis [20-24].
Μu-type opioid receptors are identified in several im-
munological cell subsets [25,26], and it has been demon-
strated that opioids suppress T cell functioning and the
production of several cytokines [23,27-29]. Activation of
the μ-opioid receptor expressed on endothelial cells stim-
ulates angiogenesis and a synergistic effect of morphine
sulphate with VEGF has been demonstrated [21,30,31].
Methylnaltrexone could be of additive value to prevent
this unwanted immunomodulatory and angiogenic activity
of opioids [30]. Therefore, we will study the effects of
methylnaltrexone on immunomodulatory and angiogenic
activity in patients during treatment with this agent.
Aims
Primary aim of the study is to compare the efficacy of a
fixed dose of subcutaneous methylnaltrexone to induce
laxation in patients who suffer from constipation due to
either fentanyl, oxycodone or morphine sulphate despite
optimal prophylactic laxative use.
Secondary aims are 1) to determine size, phenotype, and
function of various leukocyte subsets as well as serum
cytokine levels during treatment with the μ-opioid receptor
antagonist methylnaltrexone and 2) to determine whether
systemic antagonistic treatment with methylnaltrexone will
modify systemic biomarkers of angiogenesis.
Methods
This study is a multi-center, prospective, parallel-group,
observational study to compare the efficacy of methyl-
naltrexone between patient groups using different types
of opioids. The immunomodulatory and anti-angiogenic
effects of methylnaltrexone will be evaluated in a subset
of patients included in the VU University medical center.
The trial will be conducted in accordance with the Declar-
ation of Helsinki and Good Clinical Practice guidelinesand has been approved by the Medical research Ethics
Committee of the VU University medical center and the
institutional ethics committees of the other participating
sites. Patient recruitment and data collection started in
July 2012. A study flow chart is provided in Figure 1.
Patients
Patients are recruited from the outpatient clinics and the
inpatient wards of a University medical center, three teach-
ing hospitals and a high care hospice in the Netherlands.
We ask patients for informed consent to participate in this
study if they suffer from OIC caused by morphine, oxy-
codone or fentanyl, despite prophylactic laxative use. Pa-
tients should use only one subtype of maintenance opioids,
but (short-acting) rescue doses of another opioid subtype
are allowed for up to two doses a day. Rescue doses of a
short-acting form of the same opioid subtype as the main-
tenance opioid can be used in any dosing frequency. With
this maximum of two doses the rescue opioid will not have
a therapeutic level during a significant part of the day [13].
Patients should be on a stable laxative regimen for at
least 3 days before the first dose of methylnaltrexone.
This is defined as at least one type of laxative in an ad-
equate dosing regimen, (e.g. macrogol 2 packets daily,
magnesium(hydr)oxide 500 mg three times daily, bisaco-
dyl 10 mg daily or sennoside A + B 10 ml daily) or at
least two types of laxatives in a suboptimal dose with pa-
tient characteristics hampering optimal treatment.
Further inclusion criteria are that the patient should be
aged ≥18 years; receives supportive care for any medical
condition that requires prolonged opioid use (e.g. cancer
or chronic obstructive pulmonary disease); is able to pro-
vide informed consent; has an opioid induced change in
his/her laxation pattern with <3 bowel movements in the
past week, and no bowel movement in the past 24 hours,
or no bowel movement in the past 48 hours.
Exclusion criteria for participation are previous treat-
ment with methylnaltrexone; a life expectancy of less
than two weeks; presence of a fecal ostomy or an intra-
peritoneal catheter; clinically relevant active diverticular
disease; body weight <38 kg; and contra-indications for
methylnaltrexone use, such as a suspected mechanical
gastrointestinal obstruction, impaired renal function
(eGFR <30 ml/min/1.73 m2 or requiring dialysis), preg-
nancy or lactation, treatment with an investigational
product, and presence of another, more probable cause
of constipation. Presence of the latter is discussed be-
tween the patients physician and the investigator, and
if necessary additional imaging or laboratory analysis is
performed. Patients should be excluded if there are
clinical abnormalities present that may interfere with
participation or compliance to the study. Additional ex-
clusion criterion for the laboratory part of the study is the







Inclusion and baseline BFI
Treatment with methylnaltrexone and laxation 
diary for 14 days
Study completion + end of study BFI
morphine oxycodone fentanyl
ITT-cohort
Figure 1 Study flow chart.
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the use of corticosteroids ≥ 30 mg prednisolone or equiva-
lent in the past two weeks.
Randomization, blinding and treatment allocation
Since all patients have an indication for treatment with
methylnaltrexone and literature has already shown better
responses to methylnaltrexone than to placebo, there
will be no placebo treatment arm.
All patients receive the same dosing schedule of methyl-
naltrexone; there will be no randomization or blinding
procedure. Study groups are defined by the type of opioid
used by the patient, being either morphine sulphate, fen-
tanyl or oxycodone.
Treatment
Patients will be treated with methylnaltrexone in a
standard dosing regimen for their weight:
38–62 kg: 8 mg
62–114 kg: 12 mg
>114 kg: 0.15 mg/kgMethylnaltrexone will be administered subcutaneously
every other day for up to 7 doses. Treatment with methyl-
naltrexone will be continued for up to 14 days. If desired,
the patient may continue methylnaltrexone treatment
after finishing the 14-day study treatment.
While enrolled in this study, it is not allowed to use
rescue laxatives or enemas 4 hours before and/or after
methylnaltrexone administration. Rescue laxatives are
defined as laxatives which are not prescribed on a regu-
lar basis at the start of the study, and might be needed
if methylnaltrexone is not effective. Standing laxative
orders and opioid treatment will be continued during
the study, but can be modified according to clinical
judgment if diarrhea occurs or constipation persists. If
needed, opioid dosing can be increased, however not de-
creased to a level below baseline. The use of spasmolytic
drugs to relieve abdominal cramps is permitted in this
trial.
Study measurements
Demographic and baseline data of each patient will be
extracted from his/her medical record and checked with
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which the patient uses opioids, the daily dose of the spe-
cific opioid subtype the patient uses, and the type and
dose of laxatives the patient uses.
Patients will be asked to complete a laxation diary
from day −3 up to day 14, and the Bowel Function Index
(BFI) on day 0 and 14. In the laxation diary the time
of administration of methylnaltrexone is noted, as well
as the timing, consistency and volume of bowel move-
ments. Patients also note an average pain score for each
day, the occurrence of side effects and use of rescue lax-
atives in the laxation diary. The BFI consists of three
questions about symptoms of constipation experienced
during the past week. Answers to these questions are
rated on a scale from 0 to 100 and the final score is cal-
culated by the mean of the three answers. A decrease of
12 points or more between start and end of the study is
thought to be a clinically significant response [32].
From patients taking part in the exploratory study,
blood will be drawn before the first administration of
methylnaltrexone (day 0), after 24 hours (day 1), at day
14 and around day 42 for immuno- and angiogenic
measurements.
Non-responders
If the patient has no response to the first 4 administra-
tions of methylnaltrexone (first week of treatment) the
treatment will be halted. Patients should still complete
the diary and BFI according to the study schedule.
Adverse events
Adverse events are defined as any undesirable experi-
ence occurring to a patient during the study, whether
or not considered related to the treatment. All adverse
events reported spontaneously by the patient or ob-
served by the investigator or his staff will be recorded
and graded according to the common terminology cri-
teria for adverse events version 4.0. All adverse events
will be followed until they have abated, or until a stable
situation has been reached. Depending on the event, fol-
low up may require additional tests or medical procedures
as indicated, and/or referral to the general physician or a
medical specialist.
Diarrhea, abdominal cramps or sudden increase of pain
grade 3 according to the Common Terminology Criteria
for Adverse Events (CTCAE), that is related to the study
drug according to the investigator, could be reason to skip
the next dose of methylnaltrexone.
If these side-effects re-appear after the following dose,
the treatment with methylnaltrexone should be halted.
Patients will be asked to complete the laxation diary and
BFI according to the study schedule. Patients participat-
ing in the laboratory part of the study will be withdrawn
from this part of the study.Diarrhea, abdominal cramps or sudden increase of
pain grade 4 according to the CTCAE, that is related to
the study drug according to the investigator, would be
reason to stop treatment with methylnaltrexone. Patients
will be asked to complete the laxation diary and BFI ac-
cording to the study schedule, if possible. Patients par-
ticipating in the laboratory part of the study will be
withdrawn from this part of the study.
Endpoints
Primary endpoint is the proportion of patients that has a
rescue-free laxation response within 4 hours after at
least 2 of the first 4 doses (the first week of treatment).
Secondary endpoints are the time to first laxation, re-
sponse percentages within 4 or 24 hours after the first
and consecutive methylnaltrexone administrations, the
number of laxations per week and the change in BFI
score between day 0 and 14.
Additional study parameters are the change in leukocyte
subsets and serum cytokine levels, angiogenic blood factor
concentrations, level of endothelial progenitor cells, and
angiogenic potential determined with in vitro endothelial
cell proliferation assays.
Sample size calculation and statistical analysis
Opioid treatment may cause constipation, but constipa-
tion may also have another etiology. In calculating the
number of patients per group we assumed OIC in con-
stipated patients treated with fentanyl to be 40% and in
patients treated with morphine sulphate or oxycodone
to be 70 and 75% [8]. Based on the receptor-profile and
pharmacokinetics of the different opioids [13] we
hypothesize that methylnaltrexone will induce success-
ful laxation in 60% of the patients in the morphine
group, 60% of the patients in the oxycodone group and
in 25% of the patients in the fentanyl group within
4 hours after at least 2 of the first 4 doses (Table 2).
For testing two hypotheses, being a 35% difference in
response rate between the morphine group vs. the fen-
tanyl group and a 35% difference in response rate be-
tween the oxycodone group vs. the fentanyl group, we
used a corrected α of .025 instead of .05. This hypoth-
eses will be tested against the null-hypothesis that there is
no difference between the efficacy of methylnaltrexone be-
tween the different opioid subtypes. Calculation of the
sample size performed with STATA 11, using a power of
0.8 and an α of .025 in a two sided test, results in 62 pa-
tients in the morphine sulphate group, 62 patients in the
oxycodone group and 31 patients in the fentanyl group.
Taking into account an expected drop-out rate of 20% we
aim to include 78, 78 and 39 patients respectively.
Based on the sample size of the three groups it seems
feasible to include 20 patients of each group in the ex-
ploratory part of the study, in which the immunologic
Table 2 Expected response rate to methylnaltrexone
Opioid Probability that constipation
is opioid induced
Occupation of the peripheral μ receptor
by opioid subtype
Expected response rate to
methylnaltrexone
Morphine Sulphate 70% High 60%
Oxycodone 75% Intermediate-high 60%
Fentanyl 40% Low 25%
Based on the data in Table 1, we expect a high probability that the constipation is opioid induced for morphine sulphate and oxycodone. This is in contrast with
a low probability that it is opioid induced for fentanyl. Because morphine sulphate primarily acts on the peripheral mu receptor, we expect a good response rate
to methylnaltrexone. The combination of a high probability that the constipation is opioid induced in the oxycodone group, with its activity on both the central
and the peripheral mu, kappa, and gamma receptor leads to an expected response rate that equals that of morphine sulphate. For the fentanyl group both the
low probability that the constipation is opioid induced, and the sequestration in the central nerve system lead to a very low expected response rate
to methylnaltrexone.
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This sample size seems to be large enough to account
for the inter individual differences in the results found
in previous studies on this subject.
Data will be anonymized and collected in an web-
based database system (Open Clinica). Statistical analysis
will be performed in SPSS version 20. The primary end-
point will be expressed in the proportion of patients hav-
ing rescue-free laxation response within 4 hours after at
least 2 of the first 4 doses and significance will be evalu-
ated by the χ2 test.
The proportion of patients fulfilling the secondary end
points will also be evaluated by the χ2 test. The time to
laxation, the number of laxations per week, the change
in BFI score and the data from the laboratory part will
be continuous variables and will therefore be presented
by their mean and standard deviation and analyzed by
means of the student t-test, Mann–Whitney U test, or
ANOVA, whichever is considered most appropriate.
Discussion
Constipation is one of the most common symptoms in
palliative care, and is frequently caused by opioids. Des-
pite prophylactic laxatives, up to 20 percent of patients
using opioids will develop opioid induced constipation
(OIC). Methylnaltrexone, a peripherally acting μ-opioid
receptor antagonist, is designed to displace the opioid
from peripheral receptors in the gut, thereby decreasing
the opioid's constipating effects and inducing laxation,
without reducing analgesia.
In current practice it is used as rescue medication after
failure of standard (combination) laxative therapy. Methyl-
naltrexone prescribed in an earlier stage could avoid se-
vere OIC symptoms. The reasons for this rescue strategy
are mainly based on the fact that methylnaltrexone has
only been tested as rescue medication for OIC and that
the costs of methylnaltrexone are higher than those of
other laxatives. Reports of gastrointestinal perforations
after use of methylnaltrexone might have resulted in more
reluctance to prescribe this drug [33]. Another important
factor that tempers the use of methylnaltrexone is the
observation that only half of the patients respond to thistreatment. We hypothesize that the response rate is
dependent on the receptor profile of the opioid that is
causing constipation. Consequently, it should be possible
to optimize clinical benefit of methylnaltrexone by pre-
scribing this in an earlier stage of constipation treatment
to patients who are likely to respond. In this study we will
evaluate differences in efficacy of methylnaltrexone in re-
ducing OIC between the commonly prescribed opioid
subtypes morphine sulphate, oxycodone and fentanyl.
As this is a prospective study, we have the benefit
of adequate power compared to a subset analysis of pre-
vious studies. We will evaluate the objective response
(number of laxations) in combination with the clinical
benefit as is rated on the Bowel Function Index.
In this study the opioid subtypes the patients are using
are not randomized, but based on the preference of the
treating physician and the side effects experienced by pa-
tients. Although this might influence the incidence of
OIC, it should not influence the efficacy of methylnal-
trexone for a specific opioid subtype.
We have not included a placebo treatment group, be-
cause methylnaltrexone is already proven effective and
cannot be withheld from patients for ethical reasons.
In this study rescue opioids of a different subtype than
the maintenance opioid are allowed, with a maximum
of two rescue doses per day. This decision is based on
the fact that in daily practice a majority of patients use
opioid combination regimens with a difference in pre-
scribed subtypes of rescue- and maintenance opioids.
We have set a cut-off at two rescue-opioid doses a day.
This is based on the pharmacokinetic properties of res-
cue opioids, which will not have therapeutic levels during
a significant part of the day when they are administered
twice a day [13]. The possibility that these rescue opioids
contribute to the development of OIC, even in these low
doses, can however not be ruled out.
The exploratory laboratory part of this study is of par-
ticular interest when the anti-angiogenic and immuno-
modulatory effects found in pre-clinical studies are
clinically confirmed. If methylnaltrexone inhibits this
pro-angiogenic and immunomodulatory effects of opi-
oids, a randomized controlled trial investigating the
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tumor progression and survival could be a next step.
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